Barrett's esophagus: An update

Critical Reviews in Oncology/Hematology

Volumn 46, Issue 2, 2003, Pages 187-206

  Conio, Massimo ^a   Lapertosa, Gabriella ^b   Blanchi, Sabrina ^a   Filiberti, Rosangela ^a  

^a UNIVERSITY OF GENOA   (Italy)

^b UNIVERSITY OF GENOA   (Italy)

Author keywords

Barrett's esophagus; Cardia intestinal metaplasia; Chronic gastroesophageal reflux; High grade dysplasia

Indexed keywords

AGE; ARGON PLASMA COAGULATION; BARRETT ESOPHAGUS; CANCER GRADING; CANCER INCIDENCE; CANCER PATIENT; CANCER RISK; CARDIA; DIZYGOTIC TWINS; DYSPLASIA; ENDOSCOPIC SURGERY; ENDOSCOPY; ESOPHAGEAL ADENOCARCINOMA; ESOPHAGUS CANCER; ESOPHAGUS MUCOSA; ESOPHAGUS RESECTION; FOLLOW UP; GASTROESOPHAGEAL REFLUX; GENETIC PREDISPOSITION; HEALTH SURVEY; HISTOPATHOLOGY; HUMAN; INTESTINE METAPLASIA; LOWER ESOPHAGUS SPHINCTER; MONOZYGOTIC TWINS; POPULATION; PREVALENCE; REVIEW; STANDARD; SURGICAL TECHNIQUE;

EID: 0345236606     PISSN: 10408428     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1040-8428(02)00123-3     Document Type: Review

References (224)

1. Sampliner RE, Practice Parameters Committee of the American College of Gastroenterology. Practice guidelines on the diagnosis, surveillance, and therapy of Barrett's esophagus. Am. J. Gastroenterol. 1998;93:1028-32.
2. Cameron A.J., Lomboy C.T. Barrett's esophagus: age, prevalence and extent of columnar epithelium. Gastroenterology. 103:1992;1241-1245.
3. Falk J.W. Barrett's esophagus. Gastroenterology. 122:2002;1569-1591.
4. Cameron A.J., Zinsmeister A.R., Ballard D.J., Carney J.A. Prevalence of columnar-lined (Barrett's) esophagus: comparison of population-based clinical and autopsy findings. Gastroenterology. 99:1990;918-922.
5. Conio M., Cameron A.J., Romero Y., et al. Secular trends in the epidemiology and outcome of Barrett's oesophagus in Olmsted County, Minnesota. Gut. 48:2001;304-309.
6. Prach A.J., Macdonald T.A., Hopwood D.A., Johnston D.A. Increasing incidence of Barrett's oesophagus: education, enthusiasm, or epidemiology? Lancet. 350:1997;933.
7. Johnston M.H., Hammond A.S., Laskin W., Jones D.M. The prevalence and clinical characteristics of short segments of specialized intestinal metaplasia in the distal esophagus on routine endoscopy. Am. J. Gastroenterol. 91:1996;1507-1511.
8. Weston A.P., Krmpotich P., Makdisi W.F., et al. Short segment Barrett's esophagus: clinical and histological features, associated endoscopic findings, and association with gastric intestinal metaplasia. Am. J. Gastroenterol. 91:1996;981-986.
9. Crabb D.W., Berk M.A., Hall T.R., Conneally P.M., Biegel A.A., Lehman G.A. Familial gastroesophageal reflux and development of Barrett's esophagus. Ann. Int. Med. 103:1985;52-54.
10. Jochem V.J., Fuerst P.A., Fromkes J.J. Familial Barrett's esophagus associated with adenocarcinoma. Gastroenterology. 102:1992;1400-1402.
11. Cameron A.J., Lagergren J., Henriksson C., et al. Gastroesophageal reflux disease in monozygotic and dizygotic twins. Gastroenterology. 122:2002;55-59.
12. Romero Y., Cameron A.J., Locke G.R. III, et al. Familial aggregation of gastroesophageal reflux in patients with Barrett's esophagus and esophageal adenocarcinoma. Gastroenterology. 113:1997;1449-1456.
13. Trudgill N.J., Kapur K.C., Riley S.A. Familial clustering of reflux symptoms. Am. J. Gastroenterol. 94:1999;1172-1178.
14. Romero Y., Cameron A.J., McDonnell S.K., et al. Barrett's esophagus: prevalence in relatives with and without frequent symptoms. Am. J. Gastroenterol. 97:2002;1127-1132.
15. Cameron A.J. Epidemiology of columnar-lined esophagus and adenocarcinoma. Gastroenterol. Clin. N. Am. 26:1997;487-494.
16. Menke-Pluymers M.B.E., Schoute N.W., Mulder A.H., Hop W.C.J., van Blankenstein M., Tilanus H.W. Outcome of surgical treatment of adenocarcinoma in Barrett's oesophagus. Gut. 33:1992;1454-1458.
17. van Sandick J.W., van Lanschot J.J., Kuiken B.W., Tytgat G.N.J., Offerhaus G.J.A., Obertop H. Impact of endoscopic biopsy surveillance of Barrett's oesophagus on pathological stage and clinical outcome of Barrett's carcinoma. Gut. 43:1998;216-222.
18. Incarbone R., Bonavina L., Saino G., Bona D., Peracchia A. Outcome of esophageal adenocarcinoma detected during endoscopic biopsy surveillance for Barrett's esophagus. Surg. Endosc. 16:2002;263-266.
19. Dent J., Dodds W.J., Friedmann R.H., et al. Mechanism of gastroesophageal reflux in recumbent asymptomatic human subjects. J. Clin. Invest. 65:1980;256-267.
20. Mittal R.K., Holloway R.H., Penagini R., et al. Transient lower esophageal sphincter relaxation. Gastroenterology. 109:1995;601-610.
21. Singh P., Taylor R.H., Colin-Jones D.G. Esophageal motor dysfunction and acid exposure in reflux esophagitis are more severe if Barrett's metaplasia is present. Am. J. Gastroenterol. 89:1994;349-356.
22. Coenraad M., Masclee A.A.M., Straathof J.W.A., et al. Is Barrett's esophagus characterized by more pronounced acid reflux than severe esophagitis? Am. J. Gastroenterol. 93:1998;1068-1072.
23. Lidums I., Holloway R. Motility abnormalities in the columnar lined esophagus. Gastroenterol. Clin. North. Am. 26:1997;519-531.
24. Zentilin P., Conio M., Mele R., et al. Comparison of the main oesophageal pathophysiological characteristics between short- and long-segment Barrett's oesophagus. Aliment. Pharmacol. Ther. 16:2002;893-898.
25. Fass R., Hell R.W., Garewal H.S., et al. Correlation of oesophageal acid exposure with Barrett's oesophagus length. Gut. 48:2001;310-313.
26. Tobey N.A., Hosseini P.S., Caymaz-Bor C., Wyatt H.R., Orlando G.S., Orlando R.C. The role of pepsin in acid injury to esophageal epithelium. Am. J. Gastroenterol. 96:2001;3062-3070.
27. Champion G., Richter J.E., Vaezi M.F., Singh S., Alexander R. Duodenogastroesophageal reflux: relationship to pH and importance in Barrett's esophagus. Gastroenterology. 107:1994;747-754.
28. Vaezi M.F., Richter J.E. Role of acid and duodenogastroesophageal reflux in gastroesophageal reflux disease. Gastroenterology. 111:1996;1192-1199.
29. Kauer W.K.H., Peters J.H., DeMeester T.R., Ireland A.P., Bremmer C.G., Hagen J.A. Mixed reflux of gastric and duodenal juices is more harmful to the esophagus than gastric juice alone. Ann. Surg. 222:1995;525-533.
30. Zhang F., Altorki N.K., Wu Y.C., Soslow R.A., Subbaramaiah K., Dannenberg A.J. Duodenal reflux induces cyclooxygenase-2 in the esophageal mucosa of rats: evidence for involvement of bile acids. Gastroenterology. 121:2001;1391-1399.
31. Triadafilopulos G. Acid and bile reflux in Barrett's esophagus: a tale of two evils. Gastroenterology. 121:2001;1502-1505.
32. Krishnadath K.K., Reid B.J., Wang K.K. Biomarkers in Barrett esophagus. Mayo Clin. Proc. 76:2001;438-446.
33. Morris C.D., Armstrong G.R., Bigley G., Green H., Attwood S.E. Cyclooxygenase-2 expression in the Barrett's metaplasia-dysplasia-adenocarcinoma sequence. Am. J. Gastroenterol. 96:2001;990-996.
34. Jones M.P., Sloan S.S., Rabine J.C., Ebert C.C., Huang C.-F., Kahrilas P.J. Hiatal hernia size is the dominant determinant of esophagitis presence and severity in gastroesophageal reflux disease. Am. J. Gastroenterol. 96:2001;1711-1717.
35. Mittal R.K., Balaban D.H. The esophagogastric junction. N. Engl. J. Med. 336:1997;924-932.
36. Csendes A., Smok G., Quiroz J., et al. Clinical, endoscopic, and functional studies in 408 patients with Barrett's esophagus, compared to 174 cases of intestinal metaplasia of the cardia. Am. J. Gastroenterol. 97:2002;554-560.
37. Cameron A.J. Barrett's esophagus: prevalence and size of hiatal hernia. Am. J. Gastroenterol. 94:1999;2054-2059.
38. Farhadi A., Fields J., Banan A., Keshavarzian A. Reactive oxygen species: are they involved in the pathogenesis of GERD, Barrett's esophagus, and the latter's progression toward esophageal cancer? Am. J. Gastroenterol. 97:2002;22-26.
39. Bremner C.G., Lynch V.P., Ellis F.H. Barrett's esophagus: congenital or acquired? An experimental study of esophageal mucosal regeneration in the dog. Surgery. 68:1970;209-216.
40. Gillen P., Keeling P., Byrne P.J., West A.B., Hennessy T.P.J. Experimental columnar metaplasia in the canine esophagus. Br. J. Surg. 75:1988;113-115.
41. Sawhney R.A., Shields H.M., Allan C.H., Boch J.A., Trier J.S., Antonioli D.A. Morphological characterization of the squamocolumnar junction of the esophagus in patients with and without Barrett's epithelium. Dig. Dis. Sci. 41:1996;1088-1098.
42. Cameron A.J., Arora A.S. Barrett's esophagus and reflux esophagitis: is there a missing link? Am. J. Gastroenterol. 97:2002;273-278.
43. Khan A.A., Burkhart C.R. Esophageal cast. J. Clin. Gastroenterol. 7:1985;409-412.
44. Fitzgerald R.C., Omary M.B., Triadafilopoulos G. Dynamic effects of acid on Barrett's esophagus: an ex vivo proliferation and differentiation model. J. Clin. Invest. 98:1996;2120-2128.
45. Jass J.R., Filipe M.I. A variant of intestinal metaplasia associated with gastric carcinoma: a histochemical study. Histopathology. 3:1979;191-199.
46. Jass J.R. Mucin histochemistry of the columnar epithelium of the oesophagus: a retrospective study. J. Clin. Pathol. 34:1981;866-870.
47. Lapertosa G, Baracchini P, Fulcheri E, GOSPE (Gruppo Operativo per lo Studio delle Precancerosi Esofagee). Mucin histochemistry in the interpretation of Barrett's esophagus: results of a multicentric study. Am. J. Clin. Pathol. 1992;98:61-66.
48. Riddell R.H. Premalignant and early malignant lesions in the gastrointestinal tract: definitions, terminology, and problems. Am. J. Gastroenterol. 91:1996;864-872.
49. Lewin K.J., Appelman H.D. Barrett's esophagus, columnar dysplasia and adenocarcinoma of the esophagus. In Atlas of Tumor Pathology. Tumors of the Esophagus and Stomach. 3rd ed. 1996;99-139 Armed Forces Institute of Pathology, Washington, DC.
50. Cameron A.J., Carpenter H.A. Barrett's Esophagus, high-grade dysplasia, and early adenocarcinoma: a pathological study. Am. J. Gastroenterol. 92:1997;586-591.
51. Schmidt H.G., Riddell R.H., Walther B., Skinner D.B., Riemann J.F. Dysplasia in Barrett's esophagus. J. Cancer Res. Clin. Oncol. 110:1985;145-152.
52. Riddell R.H., Goldman H., Ransohoff D.F., et al. Dysplasia in inflammatory bowel disease: standardized classification with provisional clinical application. Hum. Pathol. 14:1983;931-948.
53. Reid B.J., Haggitt R.C., Rubin C.E., et al. Criteria for dysplasia in Barrett's esophagus: a cooperative consensus study. Gastroenterology. 88:1985;1552.
54. Montgomery E., Bronner M.P., Goldblum J.R., et al. Reproducibility of the diagnosis of dysplasia in Barrett esophagus: a reaffirmation. Hum. Pathol. 32:2001;368-378.
55. Reid B.J., Haggitt R.C., Rubin C.E., et al. Observer variation in the diagnosis of dysplasia in Barrett's esophagus. Hum. Pathol. 19:1988;166-178.
56. Lee R.G. Dysplasia in Barrett's esophagus: a clinical pathologic study of six patients. Am. J. Surg. Pathol. 9:1985;845-852.
57. Hamilton S.R., Smith R.R. The relationship between columnar epithelial dysplasia and invasive adenocarcinoma arising in Barrett's esophagus. Am. J. Clin. Pathol. 87:1987;301-312.
58. Sontag S.J., Schnell T., Chejfec G., et al. Yearly endoscopy is not justified: surveillance every 2-3 years detects all cancers early. Gastroenterology. 116:1999;A316.
59. Reid B.J., Levine D.S., Longton G., Blount P.L., Rabinovitch P.S. Predictors of progression to cancer in Barrett's esophagus: baseline histology and flow cytometry identify low- and high-risk patient subset. Am. J. Gastroenterol. 95:2000;1669-1676.
60. Buttar N.S., Wang K.K., Sebo T.J., et al. Extent of high-grade dysplasia in Barrett's esophagus correlates with risk of adenocarcinoma. Gastroenterology. 120:2001;1630-1639.
61. Devesa S.S., Blot W.J., Fraumeni J.F. Jr. Changing patterns in the incidence of esophageal and gastric carcinoma in the United States. Cancer. 83:1998;2049-2053.
62. Spechler S.J., Zeroogian J.M., Antonioli D.A., Wang H.H., Goyal R.K. Prevalence of metaplasia at the gastro-oesophageal junction. Lancet. 344:1994;1533-1536.
63. Nandurkar S., Talley N.J., Martin C.J., et al. Short segment Barrett's oesophagus: prevalence, diagnosis and associations. Gut. 40:1997;710-715.
64. Trudgill N.J., Suvarna S.K., Kapur K.C., et al. Intestinal metaplasia at the squamocolumnar junction in patients attending for diagnostic gastroscopy. Gut. 41:1997;585-589.
65. Lembo T., Ippoliti A.F., Ramers C., et al. Inflammation of the gastro-esophageal junction (carditis) in patients with symptomatic gastro-oesophageal reflux disease: a prospective study. Gut. 45:1999;484-488.
66. Wolf C., Timmer R., Breumelhof R., Seldenrijk C.A., Smout A.J.P.M. Prolonged measurement of lower oesophageal sphincter function in patients with intestinal metaplasia at the oesophagogastric junction. Gut. 49:2001;354-358.
67. Hackelsberger A., Gunther T., Schultze V., et al. Intestinal metaplasia at the gastro-oesophageal junction: Helicobacter pylori gastritis or gastro-oesophageal reflux disease? Gut. 43:1998;17-21.
68. Chen Y.Y., Antonioli D.A., Spechler S.J., et al. Gastroesophageal reflux disease versus Helicobacter pylori infection as the cause of gastric carditis. Mod. Pathol. 11:1998;950-956.
69. Hackelsberger A., Gunther T., Schultze V., et al. Prevalence and pattern of Helicobacter pylori gastritis in the gastric cardia. Am. J. Gastroenterol. 92:1997;2220-2224.
70. Voutilainen M., Farkkila M., Mecklin J.P., et al. Chronic inflammation at the gastroesophageal junction (carditis) appears to be a specific finding related to Helicobacter pylori infection and gastroesophageal reflux disease. Am. J. Gastroenterol. 94:1999;3175-3180.
71. Marshall R.E., Anggiansah A., Owen W.J. Bile in the esophagus: clinical relevance and ambulatory detection. Br. J. Surg. 84:1997;21-28.
72. Oberg S., Peters J.H., DeMeester T.R., et al. Inflammation and specialized intestinal metaplasia of cardiac mucosa is a manifestation of gastroesophageal reflux disease. Ann. Surg. 226:1997;522-532.
73. Goldblum J.R., Vicari J.J., Falk G.W., et al. Inflammation and intestinal metaplasia of the gastric cardia: the role of gastroesophageal reflux and H. pylori infection. Gastroenterology. 114:1998;633-639.
74. Genta R.M., Huberman R.M., Graham D.Y. The gastric cardia in Helicobacter pylori infection. Hum. Pathol. 25:1994;915-919.
75. Morales T.G., Sampliner R.E., Bhattacharyya A. Intestinal metaplasia of the gastric cardia. Am. J. Gastroenterol. 92:1997;414-418.
76. Peek R.M., Vaezi M.F., Falk G.W., et al. Role of Helicobacter pylori cagA+ strains and specific host immune responses on the development of premalignant and malignant lesions in the gastric cardia. Int. J. Cancer. 82:1999;520-524.
77. Morini S., Zullo A., Hassan C., Lorenzetti R., Stella F., Martini M.T. Gastric cardia inflammation: role of Helicobacter pylori infection and symptoms of gastroesophageal reflux disease. Am. J. Gastroenterol. 96:2001;2337-2340.
78. Voutilainen M., Farkkila M., Juhola M., et al. Complete and incomplete intestinal metaplasia at the oesophageal junction: prevalences and associations with endoscopic erosive oesophagitis and gastritis. Gut. 45:1999;644-648.
79. Polkowski W., van Lanschot J.B., ten Kate F.J.W., et al. Intestinal and pancreatic metaplasia at the esophagogastric junction in patients without Barrett's esophagus. Am. J. Gastroenterol. 95:2000;617-625.
80. Goldblum J.R., Richter J.E., Vaezi M., Falk G.W., Rice T.W., Peek R.M. Helicobacter pylori infection, not gastroesophageal reflux, is the major cause of inflammation and intestinal metaplasia of gastric cardiac mucosa. Am. J. Gastroenterol. 97:2002;302-311.
81. Guelrud M., Herrera I., Essenfeld H., Castro J., Antonioli D.A. Intestinal metaplasia of the gastric cardia: a prospective study with enhanced magnification endoscopy. Am. J. Gastroenterol. 97:2002;584-589.
82. Kilgore S.P., Ormsby A.H., Gramlich T.L., et al. The gastric cardia: fact or fiction? Am. J. Gastroenterol. 95:2000;921-924.
83. Ormsby A.H., Vaezi M.F., Richter J.E., et al. Cytokeratin immunoreactivity patterns in the diagnosis of short-segment Barrett's esophagus. Gastroenterology. 119:2000;683-690.
84. El-Zimaity H.M.T., Graham D.Y. Cytokeratin subsets for distinguishing Barrett's esophagus from intestinal metaplasia in the cardia using endoscopic biopsy specimens. Am. J. Gastroenterol. 96:2001;1378-1382.
85. Klaase J.M., Lemaire L.C.J.M., Rauws E.A.J., Offerhaus G.J.A., van Lanschot J.J.B. Heterotopic gastric mucosa of the cervical esophagus: a case of high-grade dysplasia treated with argon plasma coagulation and a case of adenocarcinoma. Gastrointest. Endosc. 2001;101-104.
86. Winters C., Spurling T.J., Chobanian S.J., et al. Barrett's esophagus: a prevalent, occult complication of gastroesophageal reflux disease. Gastroenterology. 92:1987;118-124.
87. Gerson L.B., Edson R., Lavori P.W., Triadafilopulos G. Use of a simple symptom questionnaire to predict Barrett's esophagus in patients with symptoms of gastroesophageal reflux. Am. J. Gastroenterol. 96:2001;2005-2012.
88. Avidan B., Sonnenberg A., Schnell T.G., Sontag S.J. Hiatal hernia and acid reflux frequency predict presence and length of Barrett's esophagus. Dig. Dis. Sci. 47:2002;256-264.
89. Conio M., Filiberti R., Blanchi S., et al. Risk factors for Barrett's esophagus: a case-control study. Int. J. Cancer. 97:2002;225-229.
90. Campos G.M.R., De Meester S.R., Peters J.H., Oberg S., Crookes P.F., Hagen J.A. Predictive factors of Barrett esophagus: multivariate analysis of 502 patients with gastroesophageal reflux disease. Arch. Surg. 136:2001;1267-1273.
91. Jankowski J.A., Provenzale D., Moayyedi P. Esophageal adenocarcinoma arising from Barrett's metaplasia as regional variations in the west. Gastroenterology. 122:2002;588-590.
92. Blot W.J., Devesa S.S., Kneller R.W., Fraumeni J.F. Jr. Rising incidence of adenocarcinoma of the esophagus and gastric cardia. JAMA. 265:1991;1287-1289.
93. Pera M., Cameron A.J., Trastek V.F., Carpenter H.A., Zinsmeister A.R. Increasing incidence of adenocarcinoma of the esophagus and esophagogastric junction. Gastroenterology. 104:1993;510-513.
94. Wijnhoven B.P.L., Louwman M.W.J., Tilanus H.W., Coebergh J.W.W. Increased incidence of adenocarcinoma of the gastro-oesophageal junction in Dutch males since the 1990s. Eur. J. Gastroenterol. Hepatol. 14:2002;115-122.
95. Chow W.H., Blot W.J., Vaughan T.L., et al. Body mass index and risk of adenocarcinomas of the esophagus and gastric cardia. J. Natl. Cancer Inst. 90:1998;150-155.
96. Ritenbaugh C., Sampliner R., Aickin C.K., et al. Risk factors for Barrett's oesophagus: a life history approach to behavioural assessment in the distant past. Eur. J. Cancer Prev. 4:1995;459-468.
97. Gammon M.D., Schoenberg J.B., Ahsan H., et al. Tobacco, alcohol, and socioeconomic status and adenocarcinomas of the esophagus and gastric cardia. J. Natl. Cancer Inst. 89:1997;1277-1284.
98. Chow W.C., Finkle W.D., McLaughlin J.K., Frankl H., Ziel H.K., Fraumeni J.F. The relation of gastroesophageal reflux disease and its treatment to adenocarcinomas of the esophagus and gastric cardia. JAMA. 274:1995;474-477.
99. Lagergren J., Bergstrom R., Lindgren A., Nyren O. Symptomatic gastroesophageal reflux as a risk factor for esophageal adenocarcinoma. N. Engl. J. Med. 40:1999;825-831.
100. Spechler S.J., Robbins A.H., Bloomfield Rubins H., et al. Adenocarcinoma and Barrett's esophagus: an overrated risk? Gastroenterology. 87:1984;927-933.
101. Shaheen N.J., Crosby M.A., Bozymski E.M., Sandler R.S. Is there publication bias in the reporting of cancer risk in Barrett's esophagus? Gastroenterology. 119:2000;333-338.
102. Rudolph R.E., Vaughan T.L., Storer B.E., et al. Effect of segment length for neoplastic progression in patients with Barrett's esophagus. Ann. Int. Med. 132:2000;612-620.
103. Sharma P., Weston A.P., Morales T., et al. Relative risk of dysplasia for patients with intestinal metaplasia in the distal esophagus and in the gastric cardia. Gut. 46:2000;9-13.
104. Jankowski J.A., Perry I., Harrison R.F. Gastro-esophageal cancer: death at the junction. Understanding changes at molecular level could lead to screening opportunities. Br. Med. J. 321:2000;463-464.
105. Morales T.G., Camargo E., Bhattacharyya A., Sampliner R.E. Long-term follow-up of intestinal metaplasia of the gastric cardia. Am. J. Gastroenterol. 95:2000;1677-1680.
106. Weinstein W.M., Ippoliti A.F. The diagnosis of Barrett's esophagus: goblets, goblets, goblets. Gastrointest. Endosc. 44:1996;11-15.
107. Ruol A., Parenti A., Zaninotto G., et al. Intestinal metaplasia is the probable common precursor of adenocarcinoma in Barrett esophagus and adenocarcinoma of the gastric cardia. Cancer. 88:2000;2520-2528.
108. van Sandick J.W., van Lanschot J.J.B., ten Kate F.J.W., et al. Pathology of early invasive adenocarcinoma of the esophagus or esophagogastric junction. Cancer. 88:2000;2429-2437.
109. Cameron A.J., Souto E.O., Smyrk T.C. Small adenocarcinomas of the esophagogastric junction: association with intestinal metaplasia and dysplasia. Am. J. Gastroenterol. 97:2002;1375-1380.
110. Fitzgerald R.C., Saeed I.T., Khoo D., Farthing N.J.G., Burnham W.R. Rigorous surveillance protocol increases detection of curable cancers associated with Barrett's esophagus. Dig. Dis. Sci. 46:2001;1892-1898.
111. Levine D.S., Blount P.L., Rudolph R.E., Reid B.J. Safety of a systematic endoscopic biopsy protocol in patients with Barrett's esophagus. Am. J. Gastroenterol. 95:2000;1152-1157.
112. Canto M.I.F., Setrakian S., Willis J.E., Chak A., Petras R.E., Sivak M.V. Methylene blue staining of dysplastic and non-dysplastic Barrett's esophagus: an in vivo and ex vivo study. Endoscopy. 33:2001;391-400.
113. Wo J.M., Ray M.B., Mayfield-Stokes S., et al. Comparison of methylene blue-directed biopsies and conventional biopsies in the detection of intestinal metaplasia and dysplasia in Barrett's esophagus: a preliminary study. Gastrointest. Endosc. 54:2001;294-301.
114. Dave U., Shousha S., Westaby D. Methylene blue staining: is it really useful in Barrett's esophagus? Gastrointest. Endosc. 53:2001;333-335.
115. Sharma P., Topalovski M., Mayo M.S., Weston A.P. Methylene blue chromoendoscopy for detection of short-segment Barrett's esophagus. Gastrointest. Endosc. 54:2001;289-293.
116. Guelrud M., Herrera I., Essenfeld H., Castro J. Enhanced magnification endoscopy: a new technique to identify specialized intestinal metaplasia in Barrett's esophagus. Gastrointest. Endosc. 53:2001;559-565.
117. Panjehpour M., Overholt B.F., Vo-Dinh T., et al. Endoscopic fluorescence detection of high-grade dysplasia in Barrett's esophagus. Gastroenterology. 111:1996;93-101.
118. Mayinger B., Horner P., Jordan M., et al. Endoscopic fluorescence spectroscopy in the upper GI tract for the detection of GI cancer: initial experience. Am. J. Gastroenterol. 96:2001;2616-2621.
119. Endlicher E., Knuechel R., Hauser T., Szeimies R.M., Scholmerich J., Messmann H. Endoscopic fluorescence detection of low- and high-grade dysplasia in Barrett's oesophagus using systemic or local 5-aminolaevulinic acid sensitization. Gut. 48:2001;314-319.
120. Wallace M.B., Perelman L.T., Backman V., et al. Endoscopic detection of dysplasia in patients with Barrett's esophagus using light-scattering spectroscopy. Gastroenterology. 119:2000;677-682.
121. Georgakoudi I., Jacobson B.C., Van Dam J., et al. Fluorescence, reflectance, and light-scattering spectroscopy for evaluating dysplasia in patients with Barrett's esophagus. Gastroenterology. 120:2001;1620-1629.
122. Falk G.W., Catalano M.F., Sivak M.V. Jr., et al. Endosonography in the evaluation of patients with Barrett's esophagus and high-grade dysplasia. Gastrointest. Endosc. 40:1994;207-212.
123. Waxman I., Saitoh Y. Clinical outcome of endoscopic mucosal resection for superficial GI lesions and the role of high-frequency US probe sonography in an American population. Gastrointest. Endosc. 52:2000;322-327.
124. Poneros J., Brand S., Bouma B., et al. Diagnosis of specialized intestinal metaplasia by optical coherence tomography. Gastroenterology. 120:2001;7-12.
125. Zuccaro G., Gladkova N., Vargo J., et al. Optical coherence tomography of the esophagus and proxymal stomach in health and disease. Am. J. Gastroenterol. 96:2001;2633-2639.
126. Shaheen N.J., Provenzale D., Sandler R. Upper endoscopy as a screening and surveillance tool in esophageal adenocarcinoma: a review of the evidence. Am. J. Gastroenterol. 97:2002;1319-1327.
127. Macdonald C.E., Wicks A.C., Playford R.J. Ten years' experience of screening patients with Barrett's oesophagus in a university teaching hospital. Gut. 41:1997;303-307.
128. Van der Burgh A., Dees J., Hop W.C.J., et al. Oesophageal cancer is an uncommon cause of death in patients with Barrett's esophagus. Gut. 39:1996;5-8.
129. Macdonald C.E., Wicks A.C., Playford R.J. Final results from 10 year cohort of patients undergoing surveillance for Barrett's oesophagus: observational study. Br. Med. J. 321:2000;1252-1255.
130. Drewitz D.J., Sampliner R.E., Garewal H.S. The incidence of adenocarcinoma in Barrett's esophagus: a prospective study of 170 patients followed 4.8 years. Am. J. Gastroenterol. 92:1997;212-215.
131. Corley D.A., Levin T.R., Habel L.A., Weiss N.S., Buffler P.A. Surveillance and survival in Barrett's adenocarcinomas: a population-based study. Gastroenterology. 122:2002;633-640.
132. Dulai G.S., Guha S., Kahn K.L., Gornbein J., Weinstein W.M. Preoperative prevalence of Barrett's esophageal adenocarcinoma: a systematic review. Gastroenterology. 122:2002;26-33.
133. Daly J.M., Karnell L.H., Menck H.R. National Cancer Data Base report on esophageal carcinoma. Cancer. 78:1996;1820-1828.
134. Eckardt V.F., Kanzler G., Bernhard G. Life expectancy and cancer risk in patients with Barrett's esophagus: a prospective controlled investigation. Am. J. Med. 111:2001;33-37.
135. Shaheen N.J. Does surveillance endoscopy improve life expectancy in those with Barrett's esophagus? Gastroenterology. 121:2001;1516-1522.
136. Achkar J.P., Post A.B., Achkar E., Carey W.D. Risk of extraesophageal malignancy in patients with adenocarcinoma arising in Barrett's esophagus. Am. J. Gastroenterol. 90:1995;39-43.
137. Katz D., Rothstein R., Schned A., Dunn J., Seaver K., Antonioli D. The development of dysplasia and adenocarcinoma during endoscopic surveillance of Barrett's esophagus. Am. J. Gastroenterol. 93:1998;536-541.
138. Wright T.A., Gray M.R., Morris A.I., et al. Cost-effectiveness of detecting Barrett's cancer. Gut. 39:1996;574-579.
139. Ofman J.J., Lewin K., Ramers C., Ippoliti A., Lieberman D., Weinstein W. The economic impact of the diagnosis of dysplasia in Barrett's esophagus. Am. J. Gastroenterol. 95:2000;2946-2952.
140. Streitz J.M.J., Ellis F.H.J., Tilden R.L., Erickson R.V. Endoscopic surveillance of Barrett's esophagus: a cost-effectiveness comparison with mammographic surveillance for breast cancer. Am. J. Gastroenterol. 93:1998;911-915.
141. Spechler S.J. Clinical practice: Barrett's esophagus. N. Engl. J. Med. 346:2002;836-842.
142. Provenzale D., Schmitt C., Wong J.B. Barrett's esophagus: a new look at surveillance based on emerging estimates of cancer risk. Am. J. Gastroenterol. 94:1999;2043-2053.
143. Spechler J.S. Barrett's esophagus: an overrated cancer risk factor. Gastroenterology. 119:2000;587-589.
144. Haggitt C., Reid B.J., Rabinovitch P.S., Rubin C.E. Barrett's esophagus: correlation between mucin histochemistry, flow cytometry, and histologic diagnosis for predicting increased cancer risk. Am. J. Pathol. 131:1988;53-61.
145. Fitzgerald R., Triadafilopoulos G. Recent developments in the molecular characterization of Barrett's esophagus. Dig. Dis. 16:1998;63-80.
146. Meltzer S.J., Yin J., Manin B., et al. Microsatellite instability occurs frequently and in both diploid and aneuploid cell population of Barrett's-associated esophageal adenocarcinomas. Cancer. Res. 54:1994;3379-3382.
147. Gleeson C.M., Sloan J.M., McGuigan J.A., Ritchie A.J., Weber J.L., Russell S.H.E. Barrett's oesophagus: microsatellite analysis provides evidence to support the proposed metaplasia-dysplasia-carcinoma sequence. Genes Chromosomes Cancer. 21:1998;49-60.
148. Riegman P.H., Burgart L.J., Wang K.K., et al. Allelic imbalance of 7q32.3-q36.1 during tumorigenesis in Barrett's esophagus. Cancer Res. 62:2002;1531-1533.
149. Lapertosa G, Baracchini P, Fulcheri E, GOSPE (Gruppo Operativo per lo Studio delle Precancerosi Esofagee): Assessment of proliferating cell nuclear antigen expression in dysplastic intestinal-type Barrett's esophagus, Pathologica 1994;86:174-9.
150. Hong M.K., Laskin W.B., Herman B.E., et al. Expansion of the Ki-67 proliferative compartment correlates with degree of dysplasia in Barrett's esophagus. Cancer. 75:1995;423-429.
151. Yacoub L., Goldman H., Odze R.D. Transforming growth factor-alpha, epidermal growth factor receptor, and MiB-1 expression in Barrett's associated neoplasia: correlation with prognosis. Mod. Pathol. 10:1997;105-112.
152. Gulizia J.M., Wang H., Antonioli D., et al. Proliferative characteristics of intestinalized mucosa in the distal esophagus and gastroesophageal junction (short-segment Barrett's esophagus): a case-control study. Hum. Pathol. 30:1999;412-418.
153. Campomenosi P., Conio M., Bogliolo M., et al. p53 is frequently mutated in Barrett's metaplasia of the intestinal type. Cancer Epidemiol. Biomarkers Prev. 5:1996;559-565.
154. Kubba A.K., Poole N.A., Watson A. Role of p53 assessment in management of Barrett's esophagus. Dig. Dis. Sci. 44:1999;659-667.
155. Geboes K. Barrett's esophagus: the metaplasia-dysplasia-carcinoma sequence: morphological aspects. Acta. Gastroenterol. Belg. 63:2000;13-17.
156. Bian Y.S., Osterheld M.C., Bosman F.T., Benhattar J., Fontolliet C. p53 gene mutation and protein accumulation during neoplastic progression in Barrett's esophagus. Mod. Pathol. 14:2001;397-403.
157. Younes M., Ertan A., Lechago L.V., Somoano J.R., Lechago J. p53 protein accumulation is a specific marker of malignant potential in Barrett's metaplasma. Dig. Dis. Sci. 42:1997;697-701.
158. Weston A.P., Banerjee S.K., Sharma P., Tran T.M., Richards R., Cherian R. p53 protein overexpression in low-grade dysplasia (LGD) in Barrett's esophagus: immunohistochemical marker predictive of progression. Am. J. Gastroenterol. 96:2001;1355-1362.
159. Reid B.J. p53 and neoplastic progression in Barrett's esophagus. Am. J. Gastroenterol. 96:2001;1321-1323.
160. Schneider P.M., Casson A.G., Levin B., et al. Mutations of p53 in Barrett's esophagus and Barrett's cancer: a prospective study of ninety-eight cases. J. Thorac. Cardiovasc. Surg. 111:1996;323-331.
161. Reid B.J., Prevo L.J., Galipeau P.C., et al. Predictors of progression in Barrett's esophagus II: baseline 17p (p53) loss of heterozygosity identifies a patient subset at increased risk for neoplastic progression. Am. J. Gastroenterol. 96:2001;2839-2848.
162. Zhuang Z., Vortmeyer A.O., Mark E.J., et al. Barrett's esophagus: metaplastic cells with loss of heterozygosity at the APC gene locus are clonal precursor to invasive adenocarcinoma. Cancer Res. 56:1996;1961-1964.
163. Klump B., Hsieh C.J., Holzmann K., Gregor M., Porschen R. Hypermethylation of the CDKN2/p16 promoter during neoplastic progression in Barrett's esophagus. Gastroenterology. 115:1998;1381-1386.
164. Bian Y.S., Osterheld M.C., Fontolliet C., Bosman F.T., Benhattar J. p16 inactivation by methylation of the CDKN2A promoter occurs early during neoplastic progression in Barrett's esophagus. Gastroenterology. 122:2002;1113-1121.
165. Jankowski J.A., Wright N.A., Meltzer S.J., et al. Molecular evolution of the metaplasia-dysplasia-adenocarcinoma sequence in the esophagus. Am. J. Pathol. 154:1999;965-973.
166. Ransford R.A., Jankowski J.A. Genetic versus environmental interactions in the esophagitis-metaplasia-dysplasia-adenocarcinoma sequence of Barrett's esophagus. Acta Gastroenterol. Belg. 63:2000;18-21.
167. Mueller J., Werner M., Siewert J.R. Malignant progression in Barrett's esophagus: pathology and molecular biology. Cancer Res. 155:2000;29-41.
168. Nobukawa B., Abraham S.C., Gill J., Heitmiller R.F., Wu T.T. Clinicopathologic and molecular analysis of high-grade dysplasia and early adenocarcinoma in short- versus long-segment Barrett esophagus. Hum. Pathol. 32:2001;447-454.
169. Riegman P.H., Vissers K.J., Alers J.C., et al. Genomic alterations in malignant transformation of Barrett's esophagus. Cancer Res. 61:2001;3164-3170.
170. Kumble S., Omary M.B., Cartwright C.A., Triadaphilopoulos G. Src activation in malignant and premalignant epithelia of Barrett's esophagus. Gastroenterology. 112:1997;348-356.
171. Walch A., Bink K., Gais P., et al. Evaluation of c-erbB-2 overexpression and Her-2/neu gene copy number heterogeneity in Barrett's adenocarcinoma. Anal. Cell. Pathol. 20:2000;25-32.
172. Geddert H., Heep H.J., Gabbert H.E., Sarbia M. Expression of cyclin B1 in the metaplasia-dysplasia-carcinoma sequence of Barrett esophagus. Cancer. 94:2002;212-218.
173. Polkowski W., Van Lanschot J.J.B., Offerhaus G.J.A. Barrett esophagus and cancer: pathogenesis, carcinogenesis, and diagnostic dilemmas. Histol. Histopathol. 14:1999;927-944.
174. Seery J.P., Syrigos K.N., Karayiannakis A.J., Valizadeh A., Pignatelli M. Abnormal expression of the E cadherin-catenin complex in dysplastic Barrett's esophagus. Acta Oncol. 38:1999;945-948.
175. Bian Y.S., Osterheld M.C., Bosman F.T., Fontolliet C., Benhattar J. Nuclear accumulation of beta-catenin is a common and early event during neoplastic progression of Barrett esophagus. Am. J. Clin. Pathol. 114:2000;583-590.
176. van Lieshout E.M., Roelofs H.M., Dekker S., et al. Polymorphic expression of the glutathione S-transferase P1 gene and its susceptibility to
177. Brabender J., Lord R.V., Wickramasinghe K., et al. Glutathione S-transferase-pi expression is downregulated in patients with Barrett's esophagus and esophageal adenocarcinoma. J. Gastrointest. Surg. 6:2002;359-367.
178. Brabender J., Lord R.V., Danenberg K.D., et al. Upregulation of ornithine decarboxylase mRNA expression in Barrett's esophagus and Barrett's-associated adenocarcinoma. J. Gastrointest. Surg. 5:2001;174-181.
179. Menges M., Michaeli B., Pueschel W., Zeitz M., Meese E. The influence of the suppression of gastroesophageal reflux on the gene expression pattern in Barrett's oesophagus. Int. J. Oncol. 20:2002;1323-1329.
180. Sharma P. An update on strategies for eradication of Barrett's mucosa. Am. J. Med. 111:2001;147S-152S.
181. Katzka D.A., Castell D.O. Successful elimination of reflux symptoms does not insure adequate control of acid reflux in patients with Barrett's esophagus. Am. J. Gastroenterol. 89:1994;989-991.
182. Ouatu-Lascar R., Fitzgerald R.C., Triadafilopoulos G. Differentiation and proliferation in Barrett's esophagus and the effects of acid suppression. Gastroenterology. 1999;327-335.
183. Ouatu-Lascar R., Triadafilopoulos G. FACG: complete elimination of reflux symptoms does not guarantee normalization of intraesophageal acid reflux in patients with Barrett' esophagus. Am. J. Gastroenterol. 93:1998;711-716.
184. Peters F.T., Ganesh S., Kuipers E.J., et al. Endoscopic regression of Barrett's oesophagus during omeprazole treatment: a randomised double blind study. Gut. 45:1999;489-494.
185. Srinivasan R., Katz P.O., Ramakrishnan A., Katzka D.A., Vela M.F., Castell D.O. Maximal acid reflux control for Barrett's oesophagus: feasible and effective. Aliment. Pharmacol. Ther. 15:2001;519-524.
186. Csendes A., Burdiles P., Braghetto I., et al. Dysplasia and adenocarcinoma after classic antireflux surgery in patients with Barrett's esophagus: the need for long-term subjective and objective follow-up. Ann. Surg. 235:2002;178-185.
187. Fass R., Garewal H.S., Hayden C.W., Ramsey L., Sampliner R.E. Preferential repair by squamous epithelium of thermal induced injury to the proxymal stomach in patients undergoing ablation of Barrett's esophagus. Gastrointest. Endosc. 53:2001;711-716.
188. Gross C.P., Cruz-Correa M., Canto M.I., McNeil-Solis C., Valente T.W., Powe N.R. The adoption of ablation therapy for Barrett's esophagus: a cohort study of gastroenterologists. Am. J. Gastroenterol. 97:2002;279-286.
189. Sampliner R.E., Faigel D., Fennerty M.B., et al. Effective and safe endoscopic reversal of nondysplastic Barrett's esophagus with thermal electrocoagulation combined with high-dose acid inhibition: a multicenter study. Gastrointest. Endosc. 53:2001;554-558.
190. Sampliner R.E., Camargo L., Fass R. Impact of esophageal acid exposure on the endoscopic reversal of Barrett's esophagus. Am. J. Gastroenterol. 97:2002;270-272.
191. Van Laethem J.L., Peny M.O., Salmon I., Cremer M., Deviere J. Intramucosal adenocarcinoma arising under squamous re-epithelialisation of Barrett's oesophagus. Gut. 46:2000;574-577.
192. Ackroyd R., Brown N.J., Stephenson T.J., Stoddard C.J., Reed M.W. Ablation treatment for Barrett's esophagus: what depth of tissue destruction is needed? J. Clin. Pathol. 52:1999;509-512.
193. Pereira-Lima I.C., Busnello J.V., Saul C., et al. High power setting argon plasma coagulation for the eradication of Barrett's esophagus. Am. J. Gastroenterol. 95:2000;1661-1668.
194. Schultz H., Miehlke S., Antos D., et al. Ablation of Barrett's epithelium by endoscopic argon plasma coagulation in combination with high-dose omeprazole. Gastrointest. Endosc. 51:2001;659-663.
195. Morris C.D., Byrne J.P., Armstrong G.R.A., Attwood S.E.A. Prevention of the neoplastic progression of Barrett's oesophagus by endoscopic argon beam plasma ablation. Br. J. Surg. 88:2001;1357-1362.
196. Al-Kasspooles M.F., Hill H.C., Nava H.R., Smith J.L., Douglass H.O., Gibbs J.F. High-grade dysplasia within Barrett's esophagus: controversies regarding clinical opinions and approaches. Ann. Surg. Oncol. 9:2002;222-227.
197. Heitmiller R.F., Redmond M., Hamilton S.R. Barrett's esophagus with high-grade dysplasia: an indication for prophylactic esophagectomy. Ann. Surg. 224:1996;67-72.
198. Thomas P., Doddoli C., Lienne P., et al. Changing patterns and surgical results in adenocarcinoma of the oesophagus. Br. J. Surg. 84:1997;119-125.
199. Orringer M.B., Marshall B., Iannettoni M.D. Transhiatal esophagectomy: clinical experience and refinements. Ann. Surg. 230:1999;392-400.
200. Patti M.G., Corvera C.U., Glasgow R.E., Way L.W. A hospital's annual rate of esophagectomy influences the operative mortality rate. J. Gastrointest. Surg. 2:1998;186-192.
201. Begg C.B., Cramer L.D., Hoskins W.J., Brennan M.F. Impact of hospital volume on operative mortality for major cancer surgery. JAMA. 280:1998;1747-1751.
202. Watanabe H., Komukai S., Ajioka Y., Nisikura K., Hashidate H., Kajima H. Histopathology of m3 and sm1 invasive squamous cell carcinoma of the esophagus with special reference to endoscopic resection. Stomach Intestine. 33:1998;985-992. (in Japanese with English abstract).
203. Dougherty T.J., Gomer C.J., Henderson B.W., et al. Photodynamic therapy. J. Natl. Cancer Inst. 90:1998;889-905.
204. Wang K.K. Photodynamic therapy of Barrett's esophagus. Gastrointest. Endosc. Clin. N. Am. 10:2000;409-419.
205. Gossner L., Stolte M., Sroka R., et al. Photodynamic ablation of high-grade dysplasia and early cancer in Barrett's esophagus by means of 5-aminolevulinic acid. Gastroenterology. 114:1999;448-455.
206. Overholt B.F., Panjehpour M., Haydek J.M. Photodynamic therapy for Barrett's esophagus: follow-up in 100 patients. Gastrointest. Endosc. 49:1999;1-7.
207. Panjehpour M., Overholt B.F., Haydeck J.M., Lee S.G. Results of photodynamic therapy for ablation of dysplasia and early cancer in Barrett's esophagus and effect of oral steroids on stricture formation. Am. J. Gastroenterol. 95:2000;2177-2184.
208. Ell C., May A., Gossner L., et al. Endoscopic mucosal resection of early cancer and high-grade dysplasia in Barrett's esophagus. Gastroenterology. 118:2000;670-677.
209. Nijhawan P.K., Wang K.K. Endoscopic mucosal resection for lesions with endoscopic features suggestive of malignancy and high-grade dysplasia within Barrett's esophagus. Gastrointest. Endosc. 52:2000;328-332.
210. Buttar N.S., Wang K.K., Lutzke L.S., Krishnadath K.K., Anderson M.A. Combined endoscopic mucosal resection and photodynamic therapy for esophageal neoplasia within Barrett's esophagus. Gastrointest. Endosc. 54:2001;682-688.
211. Harada M., Nagashima R., Takeda H., Takahashi T. Endoscopic resection of adenocarcinoma arising in a tongue of Barrett's esophagus. Gastrointest. Endosc. 52:2000;427-429.
212. Gossner L., Stolte M., Sroka R., et al. KTP laser destruction of dysplasia and early cancer in columnar-lined Barrett's esophagus. Gastroeintest. Endosc. 49:1999;8-12.
213. Buttar N.S., Wang K.K., Leontovich O., et al. Chemoprevention of esophageal adenocarcinoma by COX-2 inhibitors in an animal model of Barrett's esophagus. Gastroenterology. 122:2002;1101-1112.
214. Gupta R.A., Dubois R.N. Cycloxigenase/inhibitor therapy for the prevention of esophageal adenocarcinoma in Barrett's esophagus. J. Natl. Cancer Inst. 94:2002;406-407.
215. Nilsson J., Skobe V., Johansson J., Willen R., Johnsson F. Screening for oesophageal adenocarcinoma: an evaluation of a surveillance program for columnar metaplasia of the oesophagus. Scand. J. Gastroenterol. 35:2000;10-16.
216. O'Connor J.B., Falk G.W., Richter J.E. The incidence of adenocarcinoma and dysplasia in Barrett's esophagus. Am. J. Gastroenterol. 94:1999;2037-2042.
217. Weston A.P., Badr A.S., Hassanein R.S. Prospective multivariate analysis of clinical, endoscopic, and histological factors predictive of the development of Barrett's multifocal high-grade dysplasia or adenocarcinoma. Am. J. Gastroenterol. 94:1999;3413-3419.
218. Weston A.P., Krmpotich P.T., Cherian R., Dixon A., Topalosvki M. Prospective long-term endoscopic follow-up of short segment Barrett's esophagus: comparison with traditional long segment Barrett's esophagus. Am. J. Gastroenterol. 92:1997;407-413.
219. Ferraris R., Bonelli L., Conio M., Fracchia M., Lapertosa G., Aste H. Incidence of Barrett's adenocarcinoma in an Italian population: an endoscopic surveillance programme. Eur. J. Gastroenterol. Hepatol. 9:1997;881-885.
220. McDonald M.L., Trastek V.F., Allen M.S., Deschamps C., Pairolero P.C. Barrett's esophagus: does an antireflux procedure reduce the need for endoscopic surveillance? J. Thorac. Cardiovasc. Surg. 111:1996;1135-1140.
221. Iftikhar S.Y., James P.D., Steele R.J., Hardkinson M. Length of Barrett's oesophagus: an important factor in the development of dysplasia and adenocarcinoma. Gut. 33:1992;1155-1158.
222. Miros M., Kerlin P., Walker N. Only patients with dysplasia progress to adenocarcinoma in Barrett's oesophagus. Gut. 32:1991;1441-1446.
223. Williamson W.A., Ellis F.H., Gibb S.P., et al. Barrett's esophagus: prevalence and incidence of adenocarcinoma. Arch. Int. Med. 151:1991;2212-2216.
224. Achkar E., Carey W. The cost of surveillance for adenocarcinoma complicating Barrett's esophagus. Am. J. Gastroenterol. 83:1988;291-294.